ATE446315T1 - Cd38-spleiss-varianten und deren anwendungen - Google Patents

Cd38-spleiss-varianten und deren anwendungen

Info

Publication number
ATE446315T1
ATE446315T1 AT05756372T AT05756372T ATE446315T1 AT E446315 T1 ATE446315 T1 AT E446315T1 AT 05756372 T AT05756372 T AT 05756372T AT 05756372 T AT05756372 T AT 05756372T AT E446315 T1 ATE446315 T1 AT E446315T1
Authority
AT
Austria
Prior art keywords
applications
splicing variants
cd38jl
provides
polypeptide
Prior art date
Application number
AT05756372T
Other languages
English (en)
Inventor
Jun Li
Xiang Li
Baerbel Losacco
Zhenhao Qi
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE446315T1 publication Critical patent/ATE446315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cleaning Implements For Floors, Carpets, Furniture, Walls, And The Like (AREA)
AT05756372T 2004-02-13 2005-02-09 Cd38-spleiss-varianten und deren anwendungen ATE446315T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54436904P 2004-02-13 2004-02-13
PCT/US2005/004357 WO2005087806A2 (en) 2004-02-13 2005-02-09 Cd38 splice variant and uses thereof

Publications (1)

Publication Number Publication Date
ATE446315T1 true ATE446315T1 (de) 2009-11-15

Family

ID=34976294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756372T ATE446315T1 (de) 2004-02-13 2005-02-09 Cd38-spleiss-varianten und deren anwendungen

Country Status (8)

Country Link
US (1) US7951933B2 (de)
EP (1) EP1716176B1 (de)
JP (1) JP4767869B2 (de)
AT (1) ATE446315T1 (de)
CA (1) CA2555541A1 (de)
DE (1) DE602005017246D1 (de)
ES (1) ES2331891T3 (de)
WO (1) WO2005087806A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6123894A (en) * 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
AU5906099A (en) * 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease

Also Published As

Publication number Publication date
JP4767869B2 (ja) 2011-09-07
WO2005087806A2 (en) 2005-09-22
ES2331891T3 (es) 2010-01-19
US7951933B2 (en) 2011-05-31
US20050202482A1 (en) 2005-09-15
DE602005017246D1 (de) 2009-12-03
JP2008504804A (ja) 2008-02-21
EP1716176A2 (de) 2006-11-02
CA2555541A1 (en) 2005-09-22
WO2005087806A3 (en) 2006-05-18
EP1716176B1 (de) 2009-10-21

Similar Documents

Publication Publication Date Title
EA201070517A1 (ru) Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики
CY1122346T1 (el) Μονοκλωνα αντισωματα εναντι tης κλαουδινης 18 για τη θεραπεια του καρκινου
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DK1492561T3 (da) Fremgangsmåde til behandling af brystkirtellidelser
ATE525392T1 (de) Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
AR055191A1 (es) Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
ATE499088T1 (de) Glp-1-fc fusionsprotein-formulierung
BRPI0517973A (pt) método para purificar o fsh
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
SE0202241D0 (sv) Novel Compounds
DK1654287T3 (da) CD20-bindende polypeptidsammensætninger
EA200870556A1 (ru) Комбинированная терапия в лечении эпилепсии и родственных расстройств
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
ATE382685T1 (de) Bakteriophagen-lysin
ATE525480T1 (de) Verwendung von a33-antigenen und jam-it
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0417992A (pt) método para purificar fsh
EA202192288A1 (ru) Соединения на основе нейрегулина-4 и способы их применения
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
DE602005017246D1 (de) Cd38-spleiss-varianten und deren anwendungen
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1716176

Country of ref document: EP